
Choisissez votre étiquette
affichée directement sur le flaconEmpagliflozin (Jardiance)
Medication
- Expédié depuis l'Allemagne
Commande
- DHL avec suivi
- Emballage discret
En un coup d'œil
Empagliflozin (Jardiance) en chiffres
Les chiffres clés de notre lexique. Faites glisser le point le long de la courbe pour voir ce qui reste après une dose, par calcul.
Article complet du lexiqueHow long does it stay in the body?
Share left after one dose, calculated with a half-life of ~12 hours
Simplified model without an absorption phase, half-life from the TPD lexicon.
Half-life
about12hours
effect lasts 24h
- Class
- SGLT2 inhibitorselective, oral
- Use
- Oralonce daily in the morning
- Sizes
- 10 to 25 mg2 sizes in the shop
What studies show
All 5 sources in the lexicon- Zinman et al., NEJM, 2015
- Packer et al., NEJM, 2020
- Anker et al., NEJM, 2021
Avis
Ce que disent les clients
Uniquement des commandes réelles qui contenaient Empagliflozin (Jardiance).
Tous les avisIl n'existe pas encore d'analyse de laboratoire pour Empagliflozin (Jardiance). Votez pourFaites-le tester vous-même, nous payons la moitiéToutes les analyses de laboratoire
Connaissances
Tout sur Empagliflozin (Jardiance)
Informations détaillées bientôt disponibles.
Is empagliflozin approved?
Yes. In the USA it has been marketed as a prescription drug since 1 August 2014. According to the label for type 2 diabetes, to reduce cardiovascular death in diabetes with cardiovascular disease and in heart failure. It is not recommended in type 1 diabetes because of the ketoacidosis risk.
How does empagliflozin work?
It blocks SGLT2 in the kidney, the transporter that takes sugar back from the urine. In a cell assay a concentration of 3.1 nM was enough for half-maximal inhibition. Of all inhibitors tested it was the most selective over the gut transporter SGLT1. The sugar is lost with the urine, independently of insulin.
What did EMPA-REG OUTCOME show?
7,020 people with type 2 diabetes and cardiovascular disease were followed for a median of 3.1 years. The primary outcome of cardiovascular death, heart attack and stroke fell from 12.1 to 10.5 percent. Cardiovascular deaths fell by 38 percent, hospitalisations for heart failure by 35 percent and deaths from any cause by 32 percent. Heart attack and stroke did not differ significantly.
Does it also work without diabetes?
In heart failure, yes. In EMPEROR-Reduced and EMPEROR-Preserved the effect was the same with and without diabetes, likewise in chronic kidney disease in EMPA-KIDNEY. With reduced ejection fraction kidney function fell by 0.55 instead of 2.28 ml per minute per year.
What is euglycaemic ketoacidosis?
Acidification of the blood by ketone bodies while blood sugar is normal or only slightly raised. On SGLT2 inhibitors the typical warning sign of high sugar is therefore missing. The medical literature describes it as a predictable, detectable and preventable risk of the drug class.
Which side effects have been described?
In EMPA-REG OUTCOME only genital infections were more common than on placebo. In EMPEROR-Reduced uncomplicated genital infections were more common, in EMPEROR-Preserved also urinary tract infections and low blood pressure. In EMPA-KIDNEY serious adverse events were equally common in both groups.
Produits associés
Produits similaires
Telmisartan
Médicaments · Cardiovasculaire Cardiovasculaire
2 tailles
Testé en laboratoire
Ivermectin
Médicaments · Estomac et foie Estomac et foie
1 taille
Fenbendazol
Médicaments · Estomac et foie Estomac et foie
1 taille
Prednisone
Médicaments · Estomac et foie Estomac et foie
1 taille
Empagliflozin (Jardiance)